NEW YORK (GenomeWeb News) – CombiMatrix today said that its suite of array CGH-based tests will be co-marketed by New York-based diagnostics lab Lenetix.
The focus of the collaboration is CombiMatrix's suite of arrays for genetic conditions, primarily its BAC HD Scan test, which identifies more than 290 genomic causes of developmental disorders. Syndromes identified by the test include Down (trisomy 21), Prader-Willi, Smith Magenis, trisomy 13, trisomy 18, and DiGeorge syndromes, among others. The collaboration also includes CombiMatrix's Prenatal Scan array CGH test, a customized test specifically designed for use in prenatal diagnostics, said CombiMatrix.
"Our collaboration with Lenetix will help us increase awareness of our tests among primary care physicians including pediatricians, genetic counselors, and obstetricians-gynecologists — key customers of Lenetix," said Mansoor Mohammed, president and CEO of Combimatrix Molecular Diagnostics, in a statement.
Financial terms of the co-marketing pact were not disclosed.